Awaiting development: Guidance and quality standards
Showing 1 to 10 of 339
Title | Type |
---|---|
12 SQ-HDM SLIT for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites in children 5 to 11 years [ID6510] | Technology appraisal guidance |
Abatacept for treating active idiopathic inflammatory myopathies [TSID10095] | Technology appraisal guidance |
Abdominal aortic aneurysm | Quality standard |
Abilify MyCite for treating bipolar disorder 1 or schizophrenia [ID3833] | Technology appraisal guidance |
Acalabrutinib for treating relapsed or refractory mantle cell lymphoma [ID6389] | Technology appraisal guidance |
Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia [ID6156] | Technology appraisal guidance |
Acne | Quality standard |
Acoramidis for treating transthyretin-mediated amyloidosis cardiomyopathy [ID6354] | Technology appraisal guidance |
Adalimumab for treating early Dupuytren's contracture [ID6276] | Technology appraisal guidance |
Adrenal dysfunction | Quality standard |